TY - JOUR
T1 - Baseline Microperimetry and OCT in the RUSH2A Study
T2 - Structure−Function Association and Correlation With Disease Severity
AU - Foundation Fighting Blindness Consortium Investigator Group
AU - Lad, Eleonora M.
AU - Duncan, Jacque L.
AU - Liang, Wendi
AU - Maguire, Maureen G.
AU - Ayala, Allison R.
AU - Audo, Isabelle
AU - Birch, David G.
AU - Carroll, Joseph
AU - Cheetham, Janet K.
AU - Durham, Todd A.
AU - Fahim, Abigail T.
AU - Loo, Jessica
AU - Deng, Zengtian
AU - Mukherjee, Dibyendu
AU - Heon, Elise
AU - Hufnagel, Robert B.
AU - Guan, Bin
AU - Iannaccone, Alessandro
AU - Jaffe, Glenn J.
AU - Kay, Christine N.
AU - Michaelides, Michel
AU - Pennesi, Mark E.
AU - Vincent, Ajoy
AU - Weng, Christina Y.
AU - Farsiu, Sina
N1 - Funding Information:
Funding/Support: This work was funded by the Foundation Fighting Blindness. Financial Disclosures: E.M.L. receives grants or contracts from Novartis, consulting fees Iveric Bio. J.L.D. receives grants awarded to UCSF from the National Eye Insitute, Foundatin Fighting Blindness, L.L. Hillblom Foundation, Biogen/Nightstarx for Xolaris natural history study, Abbvie/Allergan for RST-001 study, Acucela Inc. for SeaStar Study, and Neurotech Inc for monitoring and material support for NT-501 study, she also receives consulting fees from DTx Therapeutics, Conesight, Eloxx, Eyevensys, Editas, Helios, PYC Therapautics, ProQR, Vedere Bio II, Gyroscope (SAB), Nacuity (SAB), and SparingVision, and she serves on a monitoring or advisory board for AGTC Therapeutics (DSMC membership), ProQR (DSMC member), Spark Therapeutics (DSMC member) and serves in a leadership role as chair, scientific advisory board, Foundation Fighting Blindness. M.G.M. receives support from Foundation Fighting Blindness, grants or contracts from National Eye Institute. I.A.(none); D.G.B. receives grants or contracts from NIH-EY009076, receives payment or honoraria from AGTC, Nacuity Pharmaceuticals, ProQR, Editas, 4D Molecular Therapeutics, Novartis, participates on data safety monitoring or advisory board for ReNeuron, and serves on a SAB for Foundation Fighting Blindness. J.C. receives research funding to institution from Foundation Fighting Blindness, receives royalties or licenses from Translational Imaging Innovations-Equity Interest, Consulting fees for AGTC, Meira GTx, Optovue. J.K.C. receives personal payments from Foundation Fighting Blindness, consulting fees from DTx Pharma Therapeutics, and has stock or stock options with AbbVie. T.A.D. receives consulting fees from Novartis. A.T.F. receives grants or contracts from National Eye Institute (K12EY022299), Research to Prevent Blindness, Choroiderma Research Foundation, and Eversight, Participates on an advisory board for Foundation Fighting Blindness, and has stock with Ionis Pharmaceuticals. E.H. receives support from Henry Brent Chair for innovative pediatric ophthalmology research. A.I. receives support for the present manuscript from Foundation Fighting Blindness and Research to Prevent Blindness, Inc Unrestricted grant to Duke Eye Center, receives grants or contracts from 4D Molecular Therapeutics, Acucela, AGTC, Royalties or licenses from Springer, consulting fees from Allievex, Guidepoint, Arkin Holdings, Gyroscope/Novartis, Atheneum Partners, IQVIA, Baker Brothers, Janssen, ClearView Healthcare Partners, Kairos Ventures, Endogena, Rhythm Pharmaceuticals, GLG Group, Teladoc Health, particpatres on a data safety monitoring board for Alia Therapeutics, Janssen, and is in a leadership or fiduciary role for Blue Cone Monochromacy Families Foundation (SAB), Choroideremia Research Foundation (SAB), Foundation Fighting Blindness (SAB). C.N.K. receives consulting fees from AGTC, Spark Therapeutics, Novartis, Astena Therapeutics, Lexitas, Kiora, she receives payment or honoraria from Spark Therapeutics, and grant support from AGTC, FFB, Alekus, Gyroscope, Regenx Bio, Nightstarx Therapeutics/Biogen, Iveric Biom ProQR Therapeutics, Meira GTx/Janssen, Kodiak, 4D Therapeutics, and has Astena Therapeutics stock. M.E.P. receives consulting fees from 4D Molecular Therapetuics, Abbvie, Adverum, AGTC, Ascidian, Astellas Pharmaceuticals, Atsena, Bayer, Biogen, Blue Rock, Chlogene, DTx Therapeutics, Editas, Endogena, Eyevensys, Horama, IVERIC, Janssen, Nacuity Pharmaceuticals, Novartis, Ocugen, Ora, ProQR, PYC Therapeutics, RegenexBio, Roche, Sanofi, Saliogen, Sparing Vision, Viewpoint Therapeutics, Vedere; and participates on a data safety monitoring board or advisory board for Akous, and Gensight, and other non-financial interests with FFB for clinical trial support. C.Y.W. receives consulting fees from Allergan/Abbive, Alcon, Alimera Sciences, DORC, Regeneron, REGENXBIO, Genentech, Novartis and is a board member for American Society of Retina Specialists, American Scoiety of Cataract and Refractive Surgery and Woman in Ophthalmology. S.F. receives support for the present work from FFB, NIH/NEI (P30-EY005722), and an unrestricted grant from research to Prevent Blindness to Duke Eye Center and patents issued US patents 8,811,745, and 9,299,155, and 9,589,346, and 9,940,722. M.M. is supported by a grant from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. A.V. is supported by Foundation Fighting Blindness, USA (CD-CL-0617-0727-HSC). E.H. holds the Henry Brent Chair in innovative Pediatric Ophthalmology research. J.L.D. serves on advisory boards for the Foundation Fighting Blindness and is supported in part by the UCSF Vision Core shared resource of the NIH/NEI P30 EY002162, and by an unrestricted grant from Research to Prevent Blindness. M.E.P. serves on advisory boards for Foundation Fighting Blindness. This relationship has been reviewed and NEI P30 EY002162 - Core Grant for Vision Research, managed by OHSU. D.G.B. Birch is supported by NEI 09076. S.F. is supported in part by the NIH/NEI P30-EY005722 and by an unrestricted grant from Research to Prevent Blindness to Duke Eye Center. None of the other authors report financial disclosures or conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship. The comprehensive list of FFB Consortium Investigator Group members participating in this protocol was previously published in Duncan JL, Liang W, Maguire MG, et al. Baseline visual field findings in the RUSH2A Study: associated factors and correlation with other measures of disease severity. Am J Ophthalmol. 2020;219:87-100.
Funding Information:
Funding/Support: This work was funded by the Foundation Fighting Blindness.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/12
Y1 - 2022/12
N2 - Purpose:: To investigate baseline mesopic fundus-guided microperimetry (MP) and spectral domain optical coherence tomography (OCT) in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) study. Design:: This was a prospective natural history study. The study setting was 16 clinical sites in Europe and North America. The study population comprised individuals with Usher syndrome type 2 (USH2) (n = 80) or autosomal recessive nonsyndromic retinitis pigmentosa (ARRP) (n = 47) associated with biallelic disease-causing sequence variants in USH2A. Methods:: General linear models were used to assess characteristics including disease duration, MP mean sensitivity, and OCT intact ellipsoid zone (EZ) area. The associations between mean sensitivity and EZ area with other measures, including best corrected visual acuity (BCVA) and central subfield thickness (CST) within the central 1 mm, were assessed using Spearman correlation coefficients. The main outcome measures were the mean sensitivity on MP and the EZ area and CST on OCT. Results:: All participants (N = 127) underwent OCT, whereas MP was available at selected sites (n = 93). Participants with Usher syndrome type 2 (USH2, n = 80) and nonsyndromic autosomal recessive retinitis pigmentosa (ARRP, n = 47) had the following similar measurements: EZ area (median [interquartile range {IQR}): 1.4 [0.4, 3.1] mm2 vs 2.3 [0.7, 5.7] mm2) and CST (median [IQR] = 247 [223, 280] µm vs 261 [246, 288], and mean sensitivity (median [IQR] = 3.5 (2.1, 8.4) dB vs 5.1 [2.9, 9.0] dB). Longer disease duration was associated with smaller EZ area (P < .001) and lower mean sensitivity (P = .01). Better BCVA, larger EZ area, and larger CST were correlated with greater mean sensitivity (r > 0.3 and P < .01). Better BCVA and larger CST were associated with larger EZ area (r > 0.6 and P < .001). Conclusions:: Longer disease duration correlated with more severe retinal structure and function abnormalities, and there were associations between MP and OCT metrics. Monitoring changes in retinal structure−function relationships during disease progression will provide important insights into disease mechanism in USH2A-related retinal degeneration.
AB - Purpose:: To investigate baseline mesopic fundus-guided microperimetry (MP) and spectral domain optical coherence tomography (OCT) in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) study. Design:: This was a prospective natural history study. The study setting was 16 clinical sites in Europe and North America. The study population comprised individuals with Usher syndrome type 2 (USH2) (n = 80) or autosomal recessive nonsyndromic retinitis pigmentosa (ARRP) (n = 47) associated with biallelic disease-causing sequence variants in USH2A. Methods:: General linear models were used to assess characteristics including disease duration, MP mean sensitivity, and OCT intact ellipsoid zone (EZ) area. The associations between mean sensitivity and EZ area with other measures, including best corrected visual acuity (BCVA) and central subfield thickness (CST) within the central 1 mm, were assessed using Spearman correlation coefficients. The main outcome measures were the mean sensitivity on MP and the EZ area and CST on OCT. Results:: All participants (N = 127) underwent OCT, whereas MP was available at selected sites (n = 93). Participants with Usher syndrome type 2 (USH2, n = 80) and nonsyndromic autosomal recessive retinitis pigmentosa (ARRP, n = 47) had the following similar measurements: EZ area (median [interquartile range {IQR}): 1.4 [0.4, 3.1] mm2 vs 2.3 [0.7, 5.7] mm2) and CST (median [IQR] = 247 [223, 280] µm vs 261 [246, 288], and mean sensitivity (median [IQR] = 3.5 (2.1, 8.4) dB vs 5.1 [2.9, 9.0] dB). Longer disease duration was associated with smaller EZ area (P < .001) and lower mean sensitivity (P = .01). Better BCVA, larger EZ area, and larger CST were correlated with greater mean sensitivity (r > 0.3 and P < .01). Better BCVA and larger CST were associated with larger EZ area (r > 0.6 and P < .001). Conclusions:: Longer disease duration correlated with more severe retinal structure and function abnormalities, and there were associations between MP and OCT metrics. Monitoring changes in retinal structure−function relationships during disease progression will provide important insights into disease mechanism in USH2A-related retinal degeneration.
UR - http://www.scopus.com/inward/record.url?scp=85138501403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138501403&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2022.08.013
DO - 10.1016/j.ajo.2022.08.013
M3 - Article
C2 - 36007554
AN - SCOPUS:85138501403
SN - 0002-9394
VL - 244
SP - 98
EP - 116
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -